Treating ESBL-EC UTIs in an outpatient intravenous therapy setting

0

Abstract:

BACKGROUND/AIMS: The number of urinary tract infections (UTIs) caused by extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) is increasing. In an outpatient setting, there are limited therapeutic options to treat ESBL-producing pathogens. We evaluated the outcomes of amikacin outpatient parenteral antibiotic therapy (OPAT) for UTIs caused by ESBL-EC in patients not pre-treated with carbapenem.

METHODS: We retrospectively evaluated the outcomes of amikacin OPAT for UTIs caused by ESBL-EC.

RESULTS: From November 2011 to October 2012, eight females, who could not be hospitalized for carbapenem treatment, were treated with amikacin OPAT for nine episodes of non-bacteremic ESBL-EC UTIs. Seven of the eight patients had one or more comorbidities. Of the nine UTI cases, three had symptomatic lower UTIs and six had non-bacteremic upper UTIs. In all of the cases, symptomatic and laboratory improvements were observed following amikacin OPAT. One patient showed a delayed relapse with bilateral microabscesses 3 weeks after treatment cessation; however, a clinical and microbiological cure was eventually reached. All of the patients were able to tolerate amikacin OPAT without any significant nephrotoxicity or ototoxicity.

CONCLUSIONS: Amikacin OPAT represents a feasible therapeutic option for non-bacteremic UTIs caused by ESBL-EC in settings with limited resources.

Reference:

Cho, S.Y., Choi, S.M., Park, S.H., Lee, D.G., Choi, J.H. and Yoo, J.H. (2016) Amikacin therapy for urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. The Korean Journal of Internal Medicine. 31(1), p.156-61.

DOI: 10.3904/kjim.2016.31.1.156.

Full Text

Thank you to our partners for supporting IVTEAM

Share.

Comments are closed.

Free Email Updates
Join 5.5K IVTEAM members. Subscribe now and be the first to receive all the latest free updates from IVTEAM!
100% Privacy. We don't spam.